Company

Sick Increases Revenue in Fiscal Year 2025

Sick Increases Revenue in Fiscal Year 2025

Thanks to innovations and a focus on strategic industrial markets, Sick was able to achieve moderate revenue growth in fiscal year 2025. In a turbulent market environment, Sick maintained its position and gained market share with its sensor solutions. Profitability remains at a low level.

The year 2025 was marked by many challenges and uncertainties from both an economic and geopolitical perspective. This also shaped the business performance for the year. In addition to persistent market weakness, unfavorable exchange rates, global trade policy developments, and increasing competitive and pricing pressure—particularly from China—were significant headwinds for the Sick Group’s business performance.  

Business Performance Despite a Challenging Market Environment

Sick’s revenue rose moderately in fiscal year 2025 despite the challenging market environment, totaling 1,850 million euros. This represents a year-over-year increase of 6.5 percent. Currency effects had a negative impact: assuming average exchange rates unchanged from the previous year, revenue would have risen by 9.3 percent. Earnings before interest and taxes (EBIT) decreased slightly by 0.5 percent to 54.7 million euros, with an EBIT margin of 3.0 percent.  

In the Asia-Pacific region, Sick achieved double-digit percentage growth in revenue, particularly in China. Growth in the EMEA and Americas regions was significantly lower, at around four percent and less than three percent, respectively. The strong growth in the home market of Germany was positively influenced by one-time special effects. 

Profitability stabilized thanks to cost discipline and strong innovation 

Dr. Mats Gökstorp, Chairman of the Executive Board of Sick AG: “Given the continuing challenging macroeconomic conditions and uncertainties in many markets, we were able to increase revenue growth in 2025 within the expected range. Nevertheless, we are not entirely satisfied with the overall result, as sales and order intake remained below the levels of previous years despite the recent sustained growth momentum. Our continued high investments and expenditures on research and development form a solid foundation for the further expansion of our business activities and the Group’s future growth. At the same time, internal structures must be adapted to the new market conditions. In this regard, our focus is on the excessively high cost level in Germany.”  

Jan-H. Eberhardt, Chief Financial Officer of Sick AG: “Sick has a solid balance sheet structure. We intend to continue financing our strategic innovations from our own resources in the future so that we can capitalize on growth opportunities. In fiscal year 2025, we were able to stabilize our earnings through the consistent optimization of internal structures and processes as well as sustained cost discipline. Further improving our profitability is a key objective for our success as an independent family-owned company.”  

Number of employees remains stable

As of the balance sheet date of December 31, 2025, the SICK Group employed 10,158 people, 0.2 percent fewer than in the previous year. Research and development continued to play a key role in the company’s innovative strength in 2025 and contributed significantly to the implementation of new product ideas. 

Cautiously optimistic outlook for 2026

“For 2026, we anticipate ongoing uncertainties such as geopolitical tensions and trade policy risks stemming from persistently high tariffs, which we will address through continued measures to improve earnings and a strong market presence. The economic consequences of the war in the Middle East are currently unforeseeable. Sharply rising energy prices and disrupted supply chains are dampening expectations,” says Sick CEO Dr. Mats Gökstorp. “With intelligent sensor solutions and a clear focus on automation, logistics, and industrial AI, Sick is setting its sights on profitable growth in 2026. The combination of a clear strategy, consistent focus, and increased performance is the decisive lever for securing competitiveness, expanding market share, and positioning the company for a sustainable future,” Gökstorp continues.    

contact

Erwin-Sick-Str. 1
79183 Waldkirch
GERMANY
SICK in Social Media:
Share